Orchard Therapeutics PLC

Orchard Therapeutics — Technical Presentation (December 2022)

40 slides from Orchard Therapeutics's technical presentation, Dec 12, 2022

  1. Slide 1: OTL-201 MPS-IIIA Data IR webcast

    OTL-201 MPS-IIIA Data IR webcast December 12, 2022 Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    | Forward-looking Statements Certain information set forth in this presentation and in statements made orally during this presentation contain “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and may include,

  3. Slide 3: ASH IR Event Agenda

    | ASH IR Event Agenda AGENDA TOPIC SPEAKER Orchard’s HSC Gene Therapy and MPS-IIIA Disease Overview Bobby Gaspar, M.D. Ph.D. Orchard CEO OTL-201 ASH Update: Biochemical Data Prof. Rob Wynn Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust OTL-201 ASH Update: Clinical D

  4. Slide 4: Orchard's Vision for Severe Genetic Diseases

    | HSC= hematopoietic stem cell Orchard’s Vision for Severe Genetic Diseases TIME VALUE Execute and deliver on rare disease portfolio Continue to build out capabilities in HSC gene therapy across regulatory, manufacturing, commercialization and access Expand on HSC gene therapy approach for larger in

  5. Slide 5: HSC Gene Therapy Offers a Highly Differentiated Approach

    Other Organ Systems Areas for potential future expansion Monocyte / Macrophage T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Brain High area of focus GI Integration Self-renewal | Literature references: Alessia Capotondo, Rita Milazzo, Letterio Salvatore Politi, Angelo Quattrini, Al

  6. Slide 6: Delivering Proteins to Brain

    Delivering Proteins to Brain Potential to Treat Multi-System Neurometabolic Diseases via Cross-Correction Gene modified HSCs Blood vessels Blood-brain barrier Defective neuron Migration across blood-brain barrier Engraftment in CNS as microglial-like cells Distribution throughout brain Gene modified

  7. Slide 7: Robust Pipeline in Neurodegenerative Disorders

    | Several additional research and preclinical programs under development. *Libmeldy® is approved in the European Union, UK, Iceland, Liechtenstein and Norway. In the U.S., OTL-200 is an investigational therapy. All other therapies in our pipeline are investigational and have not been approved by any

  8. Slide 8: First Clinical Outcomes from OTL-201 POC Study

    5 patients treated between 6 – 24 months of age Median 1.5 years follow-up (range 9 – 24 months) No evidence of insertional oncogenesis or clonal dominance Robust, sustained hematological engraftment Supraphysiological levels of SGSH enzyme + normalization of heparan sulfate substrate levels Gain of

  9. Slide 9: MPS-IIIA is a Progressive and Devastating Disease

    | SGSH = N-Sulfoglucosamine Sulfohydrolase Shapiro EG, et al. J Pediatr 2016;170:278-87. Photos adapted from Natural History of Sanfilippo Syndrome in Spain; Orphanet Journal of Rare Diseases · December 2013 MPS-IIIA is a Progressive and Devastating Disease Sanfilippo Syndrome type A Pathogenic vari

  10. Slide 10: High Unmet Medical Need in MPS-IIIA

    | Valstar MJ, et al. J Inherit Metab Dis 2008;31:240-252; Sun K, et al. J Clin Pharmacol 2022;62;S79-S94 High Unmet Medical Need in MPS-IIIA with Supportive Care as Only Standard of Care Autologous HSC Gene Therapy Restoration of healthy microglia function via secretion and cross-correction Supraphy

  11. Slide 11: OTL-201 Study Background and Biochemical Data

    OTL-201 Study Background and Biochemical Data Professor Rob Wynn

  12. Slide 12: OTL-201 POC Study Design

    Primary Objectives To evaluate the safety and tolerability of the IMP To evaluate biological efficacy of the IMP post-treatment via SGSH activity in total leukocytes Secondary and Exploratory Objectives Overall Survival Peripheral engraftment Efficacy on cognitive function Impact on behavior, adapti

  13. Slide 13: OTL-201 POC Patient Recruitment

    OTL-201 POC Patient Recruitment Patient Gender Country of Referral Age at treatment Gene Variant Screening DQ Completed follow up to date IMP dose at transplant CD34+ x106/kg VCN of IMP 05-001 Female Australia 18.3 months c.364G>A (p.Gly122Arg) 110 24 months 9.28 3.54 05-002 Male Germany 8.6 months

  14. Slide 14: Rapid and Robust Engraftment

    Rapid and Robust Engraftment 05-001 IMP VCN 05-002 IMP VCN 05-004 IMP VCN 05-003 IMP VCN Engraftment was rapid: neutrophil engraftment, median: 19 days platelet engraftment, median: 28 days red blood cell engraftment, median: 25 days No evidence of clonal expansion No deaths or evidence of insertion

  15. Slide 15: SGSH Enzyme Activity – Increase in CNS and periphery

    Supraphysiological SGSH levels were detected at one month post-GT through last follow-up SGSH Activity in Leukocytes SGSH Enzyme Activity – Increase in CNS and periphery SGSH Activity in CSF CSF SGSH levels were within or above normal range at 6 months to last follow-up | 2022 ASH Annual Meeting

  16. Slide 16: Heparan Sulfate Levels – Reduction in CNS and periphery

    Rapid decreases from baseline of heparan sulfate in urine and CSF were seen in all evaluated patients. Reduction in CSF HS has never been achieved with allogeneic HSCT. Urine HS Levels CSF HS Levels Heparan Sulfate Levels – Reduction in CNS and periphery | 2022 ASH Annual Meeting

  17. Slide 17: OTL-201 Clinical Outcomes

    OTL-201 Clinical Outcomes Dr. Simon Jones

  18. Slide 18: Neurocognitive Outcomes

    Neurocognitive Outcomes 4 / 5 patients are demonstrating gain of cognitive skills in line with development in healthy children Demonstration of developmental skill acquisition and behavioral phenotype not typically seen in untreated MPS-IIIA patients Acquisition of speech, continence and complex pla

  19. Slide 19: Patient 003 Summary

    Patient 003 reached the ceiling of the Bayley scale and progressed onto the Kaufman assessment – first MPS-IIIA patient with rapidly progressive phenotype at Manchester that has completed the Kaufman assessment Pre-treatment with GT Post GT Treatment Patient 003 Summary Developmental Age Equivalent

  20. Slide 20: Slide 20

  21. Slide 21: Patient 006 Summary

    Patient 006 engaged in complex tasks and able to wear glasses and a mask Post GT Treatment Patient 006 Summary Developmental Age Equivalent Chronological Age (Months) Cognitive Age Equivalent (Months) | 2022 ASH Annual Meeting

  22. Slide 22: OTL-201 POC Conclusions

    Treatment was generally well-tolerated Robust, prompt, sustained, multi-lineage engraftment of genetically modified cells Supra-physiological levels of SGSH enzyme in leukocytes, plasma and CSF Rapid and significant reduction of substrate observed in all compartments Neurocognitive trial data is ear

  23. Slide 23: OTL-201 Program Next Steps

    Report additional biochemical and clinical outcomes Patients will be followed for a minimum of 3 years Significant medical need given there are no effective therapies Program presents multiple development and commercial synergies with Orchard’s other neurometabolic programs OTL-201 Program Next Step

  24. Slide 24: Q&A Session

    Q&A Session ©@rchard therapeutics

  25. Slide 25: Back-up Appendix

    Back-up Appendix ©@rchard therapeutics

  26. Slide 26: ASH IR Event Agenda

    | ASH IR Event Agenda AGENDA TOPIC SPEAKER Orchard’s HSC Gene Therapy and MPS-IIIA Disease Overview Bobby Gaspar OTL-201 Data Update Prof Rob Wynn Q&A Leslie Meltzer

  27. Slide 27: Engraftment Trial Patients

    4 days of MAC busulfan conditioning (8 doses) and 2 days rest prior to IMP infusion Red cell and platelet transfusions, G-CSF routinely, nutritional support and analgesia as supportive therapy through transplant Engraftment achieved in all patients Mild VOD in patient 05-002 Delayed (over 42 days) e

  28. Slide 28: SAEs

    SAEs SAE Patient Description 1 05-002 Fever, grade 2, infection following line insertion prior to conditioning 2 05-002 Sinusoidal obstructive disease (Veno-occlusive disease (VOD)) related to conditioning (busulfan) 3 05-002 Subdural haematoma. Not considered related to the IMP. Possibly related to

  29. Slide 29: Peripheral SGSH enzyme data shows supraphysiological SGSH levels

    Peripheral SGSH enzyme data shows supraphysiological SGSH levels Leukocytes CD3+ CD15+ SGSH Activity Levels

  30. Slide 30: CSF SGSH is within or above normal range

    CSF SGSH is within or above normal range at 6 months and at last follow-up Plasma CSF SGSH activity levels

  31. Slide 31: Vector Copy Number

    Vector Copy Number VCN consistent with input in IMP VCN measurable rapidly in CD15+ cells, slower in CD19+ and later in CD3+ lineages In all patients, there is no evidence of clonal expansion Bone Marrow Leukocytes CD3 CD15 CD19 05-001 IMP VCN 05-002 IMP VCN 05-004 IMP VCN 05-003 IMP VCN

  32. Slide 32: Heparan sulphate storage

    Rapid HS reductions in plasma (>82%) and urine (>90%) Reduction in CSF HS – never achieved with allogeneic bone marrow transplant Heparan sulphate storage Plasma HS Urine HS CSF HS Normal range

  33. Slide 33: Neurocognitive outcomes, Summary

    Neurocognitive outcomes, SUMMARY Change in cognitive function (age equivalent scores) against natural history of MPSIIIA Change in patient behaviour, patient QoL and daily living – data not formally presented, important to patients and to regulators Specials patient had suggested an attenuated pheno

  34. Slide 34: MPS-IIIA natural history data

    MPS-IIIA natural history data Shapiro EG, et al. J Pediatr 2016;170:278-87.

  35. Slide 35: Patient 05-001 Summary

    Patient 05-001 Summary: atent Australian patient, affected older sibling ADD NATIVE LANGUAGE Covid restrictions have hampered number of visits possible In last assessment at 18 months has: struggled with tasks involving reciprocity and copying able to continue to perform tasks which could be approac

  36. Slide 36: Patient 05-002 Summary

    Patient 05-002 Summary: + German speaking, older sibling (deceased) with MPSIIIA, unaffected twin + 24 months post-transplant (~33 months) + Most recent assessment showed change in engagement and reciprocity Clear evidence of desire to please and participate + Continuing refinements in motor perform

  37. Slide 37: Patient 05-003 Summary

    Patient 05-003 Summary: Gender Age attreatment Screening 05-003 | Female | 23.3months | 405 German speaking, no family history Seen at 24 months post-transplant last week _ Developmental Age Equivalent + Above Bayley scale AE>42 months in all areas g . iti to age appropri: (Kaufman - 3 out of 4 Sa a

  38. Slide 38: Patient 05-003 Summary

    Patient 05-003 Summary: Gender Ageattreatment Screening 05-003 | Female | 233months | 105 Developmental Age Equivalent MPSIIIA children never reach the Kaufman! £ os Senet tnee! = 4s. * Exceeded Bayley at 18 month visit - 24+ month visits not shown Kaufman -Il Assessment: aN Attempted for first time

  39. Slide 39: Patient 05-004 Summary

    Patient 05-004 Summary: MP: German speaking, older sibling (deceased) with SIA 18 months post-transplant (~2 years) Most recent assessment showed: some nice turn taking interactions very interested in drawin: Change in reciprocity since previous assessment much more Motor refinements and enjoyed run

  40. Slide 40: Patient 05-006 Summary

    Patient 05-006 Summary: Patient 05-006 Hong Kong national, speaks Cantonese, older affected sibling Last seen in person at 9 months post-transplant (as early 12 month visit) Recent 12 month video call with family and translator to complete the Vineland assessment Great evidence of reciprocity Over v

Orchard Therapeutics — Technical Presentation (December 2022) on 6ix